Kisspeptin-10 vs FOXO4-DRI
Side-by-side comparison of key properties, dosing, and research.
Sexual Health & LibidoAnti-Aging & Longevity
Kisspeptin-10Anti-Aging & Longevity
FOXO4-DRI- Summary
- Kisspeptin-10 is the biologically active C-terminal decapeptide of kisspeptin, an endogenous regulator of the reproductive axis. It acts upstream of GnRH to potently stimulate LH and testosterone release, and plays a key role in sexual arousal and libido.
- FOXO4-DRI is a D-retro-inverso peptide derived from the FOXO4 protein that selectively induces apoptosis in senescent cells. By disrupting the FOXO4-p53 interaction that keeps senescent cells alive, it triggers programmed cell death specifically in these aging, pro-inflammatory cells while sparing healthy tissue.
- Half-Life
- ~4 minutes (rapidly degraded); longer-acting analogs like TAK-448 are in development
- Estimated 2-4 hours (D-amino acid confers resistance to proteolysis)
- Admin Route
- SubQ, IV
- Subcutaneous, Intraperitoneal (research)
- Research
- —
- —
- Typical Dose
- 50–500 mcg
- 5 mg/kg in rodent studies; human equivalent approximately 0.5-1 mg/kg
- Frequency
- Once daily to every other day
- 3 consecutive days per cycle
- Key Benefits
- Potently stimulates LH and testosterone
- Enhances sexual arousal and libido
- Activates HPG axis — upstream of GnRH
- May improve fertility in hypogonadotropic hypogonadism
- Increases brain activation in sexual attraction circuits
- May restore LH pulsatility in suppressed HPG axis
- Selectively clears senescent cells (senolytics)
- Reduces senescence-associated secretory phenotype (SASP) and chronic inflammation
- Demonstrated restoration of physical fitness in aged mice
- May improve healthspan and reduce age-related tissue dysfunction
- Potential for treatment of age-related pathologies driven by cellular senescence
- Does not affect healthy non-senescent cells at therapeutic doses
- Side Effects
- Injection site reactions
- Temporary nausea
- Flushing
- Elevated LH/testosterone (intended effect)
- +1 more
- Limited human data; largely preclinical evidence
- Possible temporary inflammatory response as senescent cells are cleared (senolytic effect)
- Weight loss observed at high doses in rodent studies
- Unknown long-term safety profile in humans
- Stacks With
- —
- —